SciELO - Scientific Electronic Library Online

 
vol.129 issue1Heart transplantation as a treatment for advanced heart failureClinical use and inter rater agreement in the application of the functional independence measure author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

VEGA R, Inés et al. Hepatitis C virus in a group of hematological and oncohematological patients. Rev. méd. Chile [online]. 2001, vol.129, n.1, pp.18-22. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872001000100003.

Background: Little information is available in Chile about hepatitis C virus (HCV) in hematological and oncohematological patients. Aim: To evaluate the prevalence of hepatitis C virus markers in a group of hematological and oncohematological pediatric patients seen at Valdivia Regional Hospital. Patients and methods: Antibodies against virus C, determined by ELISA and viral RNA, determined using RT-polymerase chain reaction, were measured in 54 blood samples from children with hematological diseases (34 with Acute Lymphoblastic Leukaemia, 4 with Hodgkin Diseases, 4 with Haemolytic Anemia, 5 with Sarcomas, 2 with Non-Hodgkin Lymphoma, 2 with Thrombocytopenic Purpura, 1 with an Ependimoma, one with a Wilms Tumor and 1 with a Von Willebrand Disease). Results: All samples were negative for antibodies against hepatitis C virus. Viral RNA was found in four children, all with a diagnosis of acute lymphoblastic leukemia and who received chemotherapy and multiple transfusions. Conclusions: The prevalence of Viral RNA for hepatitis C virus in oncohematological patients in our study is high and associated with the use of chemotherapy and multiple transfusions (Rev Méd Chile 2001; 129: 18-22)

Keywords : Hematologic diseases; Hepatitis C; Hepatitis C antibodies; Polymerase chain reaction.

        · text in Spanish

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License